Compass Therapeutics, Inc. — Director's Dealing 2025

Apr 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2025-04-07

Reporting Person: Lerner Neil (CHIEF ACCOUNTING OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-04-07	Common Stock	P	20000	$1.42	Acquired	320000	Direct

Footnotes

F1: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.43 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.